.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Mallinckrodt
Baxter
Merck
Argus Health
Federal Trade Commission
Teva
Chinese Patent Office
UBS
McKinsey

Generated: November 18, 2017

DrugPatentWatch Database Preview

SEROQUEL XR Drug Profile

« Back to Dashboard

What is the patent landscape for Seroquel Xr, and when can generic versions of Seroquel Xr launch?

Seroquel Xr is a drug marketed by Astrazeneca and is included in one NDA. There is one patent protecting this drug and four Paragraph IV challenges.

The generic ingredient in SEROQUEL XR is quetiapine fumarate. There are fifty-one drug master file entries for this compound. Fifty suppliers are listed for this compound. Additional details are available on the quetiapine fumarate profile page.

Pharmacology for SEROQUEL XR

Medical Subject Heading (MeSH) Categories for SEROQUEL XR

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Astrazeneca
SEROQUEL XR
quetiapine fumarate
TABLET, EXTENDED RELEASE;ORAL022047-001May 17, 2007ABRXYesNo► Subscribe► SubscribeY► Subscribe
Astrazeneca
SEROQUEL XR
quetiapine fumarate
TABLET, EXTENDED RELEASE;ORAL022047-003May 17, 2007ABRXYesNo► Subscribe► SubscribeY► Subscribe
Astrazeneca
SEROQUEL XR
quetiapine fumarate
TABLET, EXTENDED RELEASE;ORAL022047-005Aug 11, 2008ABRXYesNo► Subscribe► SubscribeY► Subscribe
Astrazeneca
SEROQUEL XR
quetiapine fumarate
TABLET, EXTENDED RELEASE;ORAL022047-002May 17, 2007ABRXYesYes► Subscribe► SubscribeY► Subscribe
Astrazeneca
SEROQUEL XR
quetiapine fumarate
TABLET, EXTENDED RELEASE;ORAL022047-004May 17, 2007ABRXYesNo► Subscribe► SubscribeY► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: SEROQUEL XR

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Astrazeneca
SEROQUEL XR
quetiapine fumarate
TABLET, EXTENDED RELEASE;ORAL022047-001May 17, 2007► Subscribe► Subscribe
Astrazeneca
SEROQUEL XR
quetiapine fumarate
TABLET, EXTENDED RELEASE;ORAL022047-003May 17, 2007► Subscribe► Subscribe
Astrazeneca
SEROQUEL XR
quetiapine fumarate
TABLET, EXTENDED RELEASE;ORAL022047-002May 17, 2007► Subscribe► Subscribe
Astrazeneca
SEROQUEL XR
quetiapine fumarate
TABLET, EXTENDED RELEASE;ORAL022047-005Aug 11, 2008► Subscribe► Subscribe
Astrazeneca
SEROQUEL XR
quetiapine fumarate
TABLET, EXTENDED RELEASE;ORAL022047-004May 17, 2007► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV (Patent) Challenges for SEROQUEL XR

Drugname Dosage Strength RLD Submissiondate
quetiapine fumarateExtended-release Tablets150 mgSeroquel XR11/17/2008
quetiapine fumarateExtended-release Tablets50 mgSeroquel XR10/17/2008
quetiapine fumarateExtended-release Tablets400 mgSeroquel XR6/18/2008
quetiapine fumarateTablets200 mg and 300 mgSeroquel XR6/12/2008
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Healthtrust
AstraZeneca
US Army
Julphar
Farmers Insurance
Cantor Fitzgerald
Accenture
Fish and Richardson
Baxter
Daiichi Sankyo

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot